FOGPHARMA
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowled... ge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.
FOGPHARMA
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.fogpharma.com
Total Employee:
51+
Status:
Active
Contact:
617-945-9510
Email Addresses:
[email protected]
Total Funding:
184 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Design Pharmaceuticals
Design Pharma has a unique suite of proprietary technologies that enable the discovery and biosynthetic production of drug candidates.
Digbi Health
Digital health company that harnesses gut microbiome & genetic risk signals to reverse inflammatory digestive disorders, diabetes, obesity.
Droplette
Droplette is a needle-free and hand-held device that delivers large molecules deep through skin.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Current Advisors List
Current Employees Featured
Founder
Investors List
Farallon Capital Management
Farallon Capital Management investment in Series C - FogPharma
Invus
Invus investment in Series C - FogPharma
6 Dimensions Capital
6 Dimensions Capital investment in Series C - FogPharma
Casdin Capital
Casdin Capital investment in Series C - FogPharma
Blue Pool Capital
Blue Pool Capital investment in Series C - FogPharma
GV
GV investment in Series C - FogPharma
Deerfield
Deerfield investment in Series C - FogPharma
T. Rowe Price
T. Rowe Price investment in Series C - FogPharma
venBio Partners
venBio Partners investment in Series C - FogPharma
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - FogPharma
Official Site Inspections
http://www.fogpharma.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.62 K
- Host name: 255.11.72.34.bc.googleusercontent.com
- IP address: 34.72.11.255
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "FogPharma"
FogPharma Company Profile 2024: Valuation, Funding & Investors …
Information on valuation, funding, cap tables, investors, and executives for FogPharma. Use the PitchBook Platform to explore the full profile.See details»
Parabilis Medicines™ – Formerly FogPharma - Business Wire
Oct 28, 2024 Parabilis Medicines™ (formerly FogPharma), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people livingSee details»
Parabilis Medicines™ – Formerly FogPharma - BioSpace
Oct 28, 2024 Parabilis is advancing its pipeline of clinical and pre-clinical Helicon™ programs focused on compelling yet previously intractable biological targets Company’s lead program, …See details»
FogPharma - Funding, Financials, Valuation & Investors
FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.See details»
FogPharma - Contacts, Employees, Board Members, Advisors
FogPharma has 10 current employee profiles, including Founder, CEO, CSO Greg Verdine. FogPharma has 3 board members and advisors, including Rick Klausner.See details»
FogPharma Company Profile - Office Locations, Competitors, …
FogPharma has 5 employees at their 1 location and $277.79 m in total funding,. See insights on FogPharma including office locations, competitors, revenue, financials, executives, …See details»
FogPharma and ARTBIO Announce Collaboration to Co-Develop …
May 14, 2024 FogPharma and ARTBIO announced a collaboration to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with cancer.See details»
FogPharma Announces $145 Million Financing to Support …
CAMBRIDGE, Mass., March 01, 2024--FogPharma today announced the successful closing of a $145 million Series E financing round.See details»
Fog clears to reveal Parabilis, a rebranded cancer biotech with big ...
Oct 28, 2024 The fog has lifted to reveal a rebranded biotech: Parabilis Medicines. | The fog has lifted to reveal a rebranded biotech: Parabilis Medicines. Formerly called FogPharma, the …See details»
JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in ... - STAT
Jan 9, 2024 FogPharma CEO Mathai Mammen is taking the stage at #JPM24 Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against …See details»
Parabilis Medicines - Drug pipelines, Patents, Clinical trials - Synapse
May 3, 2023 FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies to design a new type of radiopharmaceutical drug for …See details»
Greg Miller, MPH, MBA – FogPharma
Greg Miller has spent the last two decades enabling therapeutics companies to reach their potential through financings and establishing strategic partnerships. Greg was most recently …See details»
FogPharma - Updates, News, Events, Signals & Triggers
FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.See details»
FogPharma pulls in $145M to support cancer drug research
Mar 1, 2024 FogPharma pulls in $145M to support cancer drug research The Series E funding round included notable venture backers such as RA Capital, Samsara Biocapital and Foresite …See details»
Terms & Conditions – FogPharma
FogPharma is pioneering a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability.See details»
FogPharma secures $145m to develop cancer therapy
Mar 4, 2024 FogPharma has secured $145m in a Series E financing round to support the clinical development of its cancer therapy FOG-001 and expedite the advancement of its Helicon …See details»
FogPharma Announces $178 Million Series D Financing to …
Nov 21, 2022 Proceeds from the Series D financing will be used to advance and accelerate FogPharma’s growing pipeline of hyperstabilized α-helical (Helicon™) polypeptide …See details»
FogPharma Announces $145 Million Financing to ... - Pharma …
Mar 5, 2024 FogPharma, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its …See details»
FogPharma Announces $178 Million Series D Financing to …
Nov 21, 2022 FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers 11/21/2022See details»